Flerie portfolio firm Prokarium posts positive interim Phase 1/1b bladder cancer data for ZH9

  • Flerie portfolio company Prokarium presented interim results from an ongoing Phase 1/1b study of ZH9 in non-muscle invasive bladder cancer at the American Urological Association annual meeting.
  • The update showed a favorable safety profile, with patients who completed the protocol remaining free of disease return at 12 months.
  • Flerie holds a 50% stake in Prokarium, positioning the readout as a key catalyst for the investment case.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.